What is a stock summary page? Click here for an overview.
Business Description
NervGen Pharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA64082X2032
Share Class Description:
NGENF: Ordinary SharesDescription
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 162.85 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.6 | |||||
| 3-Year EPS without NRI Growth Rate | 5.8 | |||||
| 3-Year FCF Growth Rate | 0.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.24 | |||||
| 9-Day RSI | 70.13 | |||||
| 14-Day RSI | 60.9 | |||||
| 3-1 Month Momentum % | -12.16 | |||||
| 6-1 Month Momentum % | 0.79 | |||||
| 12-1 Month Momentum % | 18.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | |||||
| Quick Ratio | 1.66 | |||||
| Cash Ratio | 1.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 | |||||
| Shareholder Yield % | -12.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -275.34 | |||||
| ROA % | -107.43 | |||||
| ROIC % | -212.61 | |||||
| 3-Year ROIIC % | -54.54 | |||||
| ROC (Joel Greenblatt) % | -22852.65 | |||||
| ROCE % | -313.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 23.21 | |||||
| Price-to-Tangible-Book | 26.11 | |||||
| EV-to-EBIT | -6.3 | |||||
| EV-to-EBITDA | -6.32 | |||||
| EV-to-FCF | -10.04 | |||||
| Price-to-Net-Current-Asset-Value | 26.11 | |||||
| Price-to-Net-Cash | 26.11 | |||||
| Earnings Yield (Greenblatt) % | -15.87 | |||||
| FCF Yield % | -8.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NGENF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NervGen Pharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.274 | ||
| Beta | 0.89 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.57 | ||
| Volatility % | 48.04 | ||
| 14-Day RSI | 60.9 | ||
| 14-Day ATR ($) | 0.068371 | ||
| 20-Day SMA ($) | 1.89927 | ||
| 12-1 Month Momentum % | 18.94 | ||
| 52-Week Range ($) | 1.2 - 2.42 | ||
| Shares Outstanding (Mil) | 70.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NervGen Pharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NervGen Pharma Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NervGen Pharma Corp Frequently Asked Questions
What is NervGen Pharma Corp(NGENF)'s stock price today?
The current price of NGENF is $2.09. The 52 week high of NGENF is $2.42 and 52 week low is $1.20.
When is next earnings date of NervGen Pharma Corp(NGENF)?
The next earnings date of NervGen Pharma Corp(NGENF) is .
Does NervGen Pharma Corp(NGENF) pay dividends? If so, how much?
NervGen Pharma Corp(NGENF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers